Treace Medical Concepts, Inc. (TMCI), a leading medical technology company focused on advancing surgical solutions for bunion and midfoot deformities, announced its Q2 2024 financial results, highlighting revenue growth, an expanding patent portfolio, and strategic product launches.
The company’s Q2 revenue reached $44.5 million, a 6% increase compared to the same period in 2023. This growth reflects the adoption of innovative technologies and a broadening base of over 3,000 active surgeons.
Major Financial Highlights
Treace reported a gross profit of $35.7 million, with a gross margin of 80.2%. Operating expenses increased to $57.1 million, attributed to strategic investments in sales expansion, product innovation, and corporate initiatives.
Net loss for the quarter was $21.2 million, or $0.34 per share, while adjusted EBITDA loss was $8.7 million, impacted by increased operating expenses and a customer credit loss related to a recent bankruptcy.
CHECK THIS OUT: Allient (ALNT) Achieves $5M in Annualized Savings from Efficiency Initiatives in Q2 2024
Operational and Strategic Developments
Treace continues to lead in the medical field with its patent portfolio, now holding 65 U.S. patents and 22 internationally. New product launches are planned for the second half of 2024, including an entry into the minimally invasive metatarsal osteotomy market, a significant opportunity for growth in foot surgery solutions.
Treace’s CEO, John T. Treace, stated,
“We are focused on capturing greater procedure volumes, enhancing our innovative solutions, and positioning ourselves for long-term growth.”
Financial Outlook
Treace reaffirmed its full-year 2024 revenue guidance, expecting revenues between $201 million and $211 million, reflecting 7% to 13% growth. The company also anticipates a 50% improvement in adjusted EBITDA compared to 2023.
READ ALSO: Spirit Airlines in Q2 2024: $1.28B Revenue, Plus New Travel Options and Canadian Solar (CSIQ) Reports $1.6B Revenue with Solar and Storage.
